fluoro-4-[2-[4-methylsufonyl)phenyl]-1-cyclopenten-1-yl] benzene (SC-5766), 5-(4-fluorophenyl)-1[4-(methylsufonyl)phenyl]-3-trifluoromethyl 1H-pyrazole (SC-58215), N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide (T-614); or combinations thereof. --

IN THE CLAIMS

Please **amend** the claims as follows:

30. (Amended) A pharmaceutical composition comprising an analgesic combination consisting essentially of 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof.

31. (Amended) The pharmaceutical composition according to claim 30, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof would be subtherapeutic if administered without the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof.

32. (Amended) The pharmaceutical composition according to claim 30, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof; and 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof are administered orally, via implant, parenterally, sublingually, rectally, topically, or via inhalation.

35. (Amended) The pharmaceutical composition according to claim 30, wherein the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof synergistically potentiates the effect of the oxycodone and/or at least one pharmaceutically acceptable salt thereof but the oxycodone and/or at least one pharmaceutically acceptable salt thereof does not synergistically potentiate the effect of the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof.

36. (Amended) The pharmaceutical composition according to claim 34, wherein the oral solid dosage form includes a sustained release carrier which causes the sustained release of the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof; the oxycodone and/or at least one pharmaceutically acceptable salt thereof; or both the oxycodone and/or at least one pharmaceutically acceptable salt thereof and the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof when the dosage form contacts gastrointestinal fluid.

37. (Amended) A method of effectively treating pain in humans or other mammals, comprising administering to a patient an analgesic combination consisting essentially of 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof such that the dosing interval of the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

38. (Amended) The method of claim 37, wherein the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof and the oxycodone and/or at least one pharmaceutically acceptable salt thereof are administered orally.

39. (Amended) The method of claim 37, wherein the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof and the oxycodone and/or at least one pharmaceutically acceptable salt thereof are administered in a single oral dosage form.

40. (Amended) The method of claim 37, wherein the oxycodone would be sub-therapeutic if administered without the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof.

41. (Amended) The method of claim 37, wherein the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof is administered before, simultaneously with, or after administration of the oxycodone and/or at least one pharmaceutically acceptable salt thereof, such that the dosing interval of the 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

42. (Amended) A method of reducing the oxycodone and/or at least one pharmaceutically acceptable salt thereof required to treat a patient affected with pain, comprising co-administering said oxycodone and/or at least one pharmaceutically acceptable salt thereof with 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof, to augment the analgesia attributable to said oxycodone and/or at least one pharmaceutically acceptable salt thereof during at least a portion of the dosage interval of said oxycodone and/or at least one pharmaceutically acceptable salt thereof.

43. (Amended) A method of reducing the amount of 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salts thereof required to treat a patient affected with pain comprising co-administering said 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof with an effective amount of oxycodone and/or at least one pharmaceutically acceptable salt thereof, to augment the analgesia attributable to said 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof, during at least a portion of the dosage interval of said 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof.

44. (Amended) The pharmaceutical composition according to claim 30, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 2.5 mg to about 800 mg.

45. (Amended) The method of claim 37, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 2.5 mg to about 800 mg.

REMARKS

Claims 30-45 are currently pending. Claims 30-32 and 35-45 have been amended. Support for these amended claims can be found throughout the specification, e.g., on page 8, line 27; page 12, line 19 to 22; page 13, line 15 to 19; and page 18, line 7 to 11. It is respectfully submitted that no new matter has been added by virtue of this amendment.

CONCLUSION

Applicants respectfully request that the amendments made be considered and made of record.